Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9% - Time to Sell?

Key Points

• Shares fell 6.9% to about $4.23 on Tuesday with ~1.14 million shares traded, a 57% drop from average daily volume.
• Analysts remain broadly positive with a consensus rating of "Moderate Buy" and a consensus target price of $11.09 (one Strong Buy, ten Buy, one Sell).
• Insiders sold 598,623 shares (~$2.82M) in the last 90 days leaving 3.78% insider ownership, and the company remains loss-making despite beating the latest EPS (-$0.08 vs. -$0.11) and revenue ($5.49M vs. $1.89M) estimates.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report)'s share price was down 6.9% during trading on Tuesday . The company traded as low as $4.18 and last traded at $4.2280. Approximately 1,136,258 shares were traded during trading, a decline of 57% from the average daily volume of 2,636,558 shares. The stock had previously closed at $4.54.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TSHA shares. UBS Group set a $11.00 price target on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Needham & Company LLC increased their price target on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, March 19th. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, January 5th. Chardan Capital reaffirmed a "buy" rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.09.

Taysha Gene Therapies Price Performance

The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The company has a market capitalization of $1.13 billion, a PE ratio of -12.13 and a beta of 1.02. The firm has a 50-day moving average of $4.63 and a 200 day moving average of $4.58.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 56.64%. The business had revenue of $5.49 million during the quarter, compared to analyst estimates of $1.89 million. As a group, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the sale, the insider owned 1,006,439 shares in the company, valued at approximately $4,740,327.69. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the transaction, the chief financial officer owned 1,467,635 shares in the company, valued at approximately $6,971,266.25. This trade represents a 5.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 598,623 shares of company stock worth $2,822,188 in the last 90 days. 3.78% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Marex Group plc purchased a new stake in Taysha Gene Therapies during the 2nd quarter valued at approximately $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at $31,000. ST Germain D J Co. Inc. lifted its stake in Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company's stock worth $32,000 after purchasing an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Taysha Gene Therapies during the 3rd quarter valued at about $40,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock valued at $41,000 after purchasing an additional 10,742 shares in the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.